Dermavant Sciences Ltd., a leading biopharmaceutical company headquartered in Great Britain, focuses on developing innovative therapies for dermatological conditions. Founded in 2017, Dermavant has quickly established itself in the industry, particularly in the fields of psoriasis and atopic dermatitis, with a commitment to addressing unmet medical needs. The company’s flagship product, tapinarof, is a novel topical treatment that stands out for its unique mechanism of action and efficacy in managing skin disorders. Dermavant's dedication to research and development has positioned it as a key player in the dermatology market, with significant achievements in clinical trials and regulatory advancements. As it continues to expand its operational reach, Dermavant Sciences remains at the forefront of dermatological innovation, striving to improve the quality of life for patients worldwide.
We don't have data for Dermavant Sciences Ltd., but we can show you information about their parent organization instead.
View parent company